OBJECTIVE： To observe clinical efficacy and safety of torasemide in the treatment of chronic heart failure （CHF）. METHODS： 94 patients with CHF were selected and randomly divided into control group and observation group， with 47 cases in each group. Control group were treated with routine treatment， such as bed rest， oxygen inhalation， control of total body fluid intake， routine anti-heart failure therapy and use of diuretic in 24 h. Based on the above treatment， observation group were treated with Torasemide injection with initial dose of 5-10 mg， qd， gradually increasing to 20 mg/d， maximal does of 40 mg/d. Both group received 7 days of continuous treatment. Clinical efficacies were observed in 2 groups as well as serum potassium and sodium， Scr， 24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function before and after treatment. The occurrence of ADR was compared between 2 groups. RESULTS： The total effective rate of observation group was 61.70％， which was significantly higher than that of control group （46.81％）， with statistical significance （P＜0.05）. There was no statistical significance in serum potassium and sodium and Scr between 2 groups before and after treatment （P＞0.05）. There was no statistical significance in 24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function between 2 groups before and after treatment （P＞0.05）； after treatment， 24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function of 2 groups were increased significantly， the observation group was higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Torasemide is effective for CHF， and can promote diuresis and the recovery of cardiac function with good safety.